Intracellular Signalling in Inflammatory Processes at @CBMSO_CSIC_UAM. Mad about signalling in T cells of all flavours. Current love interest: interleukin 23
1/8 New paper from our lab! We identify the Src/Abl inhibitor Dasatinib as a potent suppressor of IL-23 signalling and IL-17 production in skin inflammation.
🧪 Reveals a new IL-23–Src–mTOR axis in type 3 immunity
🔗 https://t.co/RBVKthtI45
@jacionline@CBM_CSIC_UAM
🔬 How do ageing T cells compromise intestinal homeostasis & can we reverse it?
With @mmgomezheras, we discuss how ageing T cells compromise gut and what therapeutic strategies could help restore them for healthier longevity.
👉 https://t.co/jkM2UbY2pR
#GutHealth#inflammaging
🧬 Un estudio del grupo de María Luisa Toribio @ToribioLab revela que pequeñas moléculas producidas por el organismo podrían ayudar a frenar el crecimiento de la leucemia linfoblástica aguda de células T (LLA-T), uno de los tipos más agresivos de leucemia.
https://t.co/W6N1isknY0
Excited to share that our latest work is nearly out!
We uncover a tumor suppressor role of the miR-15b/16-2 cluster in T-ALL.
Stay tuned! Coming soon in @BloodPortfolio
Paper out 🎆🎆🎆 Check our latest publication 👇
Here, we propose an emerging role for the extracellular matrix as a driver of senescent cell accumulation during aging 👨🦳👵
Hope you guys like it! Open to any feedback/suggestions/critiques 😊
https://t.co/rK2pA54D33
🚨 New paper from @MMittelbrunn Lab @CBM_CSIC_UAM
We show that butyrate extends health and lifespan in mouse models of mitochondrial disease — highlighting a powerful link between mitochondrial dysfunction and the gut microbiota
🔗 Read the paper here: https://t.co/euNOZ1xBYL
3️⃣0️⃣0️⃣ es el número de participantes que necesitamos para el estudio de #celiaquía 🔛
Hemos llegado al ecuador en este reto de mejorar tratamientos y crear soluciones más efectivas.
¿Nos ayudáis a cumplirlo?
🙋🏼♂️ https://t.co/w8vW9PmRes
#dietasingluten#CD3Dtech@ComunidadMadrid
Also @CayuelaIgnacio Lis and Jorge from the @mnnavarro_lab at @CBM_CSIC_UAM talked about how IL-23-driven signalling shapes γδ17 T cell responses in skin inflammation 🧬
Their studies converge on understanding and modulating key pathways in psoriasis and inflammatory disease 💊
Very happy to share our latest lab work published in Leukemia, in which we identify the microRNA miR-28 as an effective inhibitor of ibrutinib resistance in ABC-DLBCL https://t.co/VWQMmts5vv
1/8 New paper from our lab! We identify the Src/Abl inhibitor Dasatinib as a potent suppressor of IL-23 signalling and IL-17 production in skin inflammation.
🧪 Reveals a new IL-23–Src–mTOR axis in type 3 immunity
🔗 https://t.co/RBVKthtI45
@jacionline@CBM_CSIC_UAM
💊Un fármaco aprobado para otro uso reduce la inflamación en la psoriasis en un modelo experimental
🔬Un estudio del @CBM_CSIC_UAM identifica un mecanismo desconocido hasta ahora que controla la producción de moléculas inflamatorias en esta enfermedad
➡️ https://t.co/vvvNOJ5EQd
8/8 Take-home: Targeting Src signalling can suppress IL-23–driven type 3 immunity.
Dasatinib - candidate for drug repurposing in psoriasis and related diseases.
Big thanks to all co-authors & collaborators 🙌 @CayuelaIgnacio@LabTraba#Psoriasis#Inflammation#Tcells#γδ17
7/8 We identify the Src kinase Blk as a key player in γδ17 T cells: Loss-of-function experiments show that Blk is required for mTORC1 activation and IL-17 production in response to IL-23.
Registration now open: 2026 #EMBO#Ubiquitin Workshop set in stunning Monopoli, Puglia 🇮🇹
Cutting edge science, great speakers, short talk opportunities, travel awards
Limited spaces. Dont miss out - register early!
Registration & more info: https://t.co/O29ToXHgoR